REPLIGEN CORP Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
REPLIGEN CORP (RGEN) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value of $101.47 million as of 2023-03-31, per its 10-Q filed 2023-05-02.
Discontinued › Notes › Investments › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate · last filed 2023-05-02
- 2023-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $101.47M.
- 2022-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value $100.32M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value |
|---|---|
| 2023-03-31 | $101.47M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $100.32M 10-Q · filed 2023-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |